aTYR PHARMA (ATYR) Total Liabilities (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Total Liabilities came in at $79.7 million in Q1 2026, down 18.09% YoY from $97.2 million in Q1 2025, and down 14.35% on a QoQ basis from $93.0 million in Q4 2025.
aTYR PHARMA (ATYR) Total Liabilities (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Total Liabilities data on file, last reported at $79.7 million in Q1 2026.
- Quarterly Total Liabilities fell 18.09% year-over-year to $79.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.7 million (down 18.09% YoY) and the FY2025 annual result came in at $93.0 million, down 3.95% from the prior year.
- Total Liabilities eased to $79.7 million in Q1 2026, from $93.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $136.8 million in Q1 2023 to a low of $79.7 million in Q1 2026.
- A 5-year average of $105.5 million and a median of $101.5 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 95.97% — and 2024, when it retreated 26.75%.
- Tracing ATYR's Total Liabilities over 5 years: stood at $95.8 million in 2022, then rose by 25.96% to $120.7 million in 2023, then decreased by 19.75% to $96.8 million in 2024, then dropped by 3.95% to $93.0 million in 2025, then dropped by 14.35% to $79.7 million in 2026.
- The last three Total Liabilities figures came in at $79.7 million (Q1 2026), $93.0 million (Q4 2025), and $106.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 69.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.83 Mn |
| Mar 31, 2026 | 79.65 Mn |
| Dec 31, 2025 | 93.00 Mn |
| Sep 30, 2025 | 106.65 Mn |
| Jun 30, 2025 | 101.53 Mn |
| Mar 31, 2025 | 97.25 Mn |
| Dec 31, 2024 | 96.83 Mn |
| Sep 30, 2024 | 91.62 Mn |
| Jun 30, 2024 | 105.94 Mn |
| Mar 31, 2024 | 113.25 Mn |
| Dec 31, 2023 | 120.65 Mn |
| Sep 30, 2023 | 125.07 Mn |
| Jun 30, 2023 | 132.75 Mn |
| Mar 31, 2023 | 136.84 Mn |
| Dec 31, 2022 | 95.79 Mn |
| Sep 30, 2022 | 96.06 Mn |
| Jun 30, 2022 | 96.02 Mn |
| Mar 31, 2022 | 104.78 Mn |
| Dec 31, 2021 | 115.54 Mn |
| Sep 30, 2021 | 123.92 Mn |